ArticleJournal of neurology2025

Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study.

Piero Barbanti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.